Pharsight

Salonpas generic

Salonpas is an over-the-counter topical pain reliever owned by Hisamitsu Pharmaceutical Co. The active ingredients in Salonpas are Menthol and Methyl Salicylate. The drug was first authorized for market use on February 20, 2008, and is available in patch and topical dosage forms. Salonpas holds a total of 2 drug patents.

When will Salonpas generic be available?

The generics of Salonpas are anticipated to become available after January 3, 2030. This is due to the expiration date of the patent, US8809615, titled 'Adhesive preparation', which will be expiring on January 3, 2030.

Salonpas uses

Salonpas is intended to relieve mild to moderate pain caused by muscle strains, sprains, bruising and arthritis. The active ingredient, Menthol, induces a cooling sensation that helps to numb the area, providing pain relief. Methyl Salicylate, another active ingredient in Salonpas, works by decreasing swelling and pain in the muscles and joints.

Salonpas patent expiration

Two crucial patents related to Salonpas are 'Adhesive preparation' patents marked as US9233184 (expires on August 1, 2027) and US8809615 (expires on January 3, 2030). The availability of Salonpas generic may not be possible until the last patent expires. Below are the details of the patent:

Salonpas dosage

Want to ask something?